Tumour-associated macrophages as treatment targets in oncology.
Tumour-associated macrophages as treatment targets in oncology.
复制标题
DOI：
10.1038/nrclinonc.2016.217
复制
发表时间：
2017-07
期刊：
影响因子：
--
通讯作者：
Allavena P
中科院分区：
文献类型：
--
作者：
Mantovani A;Marchesi F;Malesci A;Laghi L;Allavena P
巨噬细胞是促肿瘤炎症的关键驱动因素。肿瘤相关巨噬细胞（TAM）在不同水平上促进肿瘤进展，包括促进遗传不稳定性，培育癌症干细胞，为转移铺平道路，驯服保护性适应性免疫。TAM可以对细胞减灭治疗（化疗和放疗）的有效性产生双重阴阳影响，通过协调肿瘤促进组织修复反应来拮抗抗肿瘤活性，或者相反，有助于其最终的抗肿瘤疗效。TAM表达T细胞活化的检查点的触发物，并且是检查点阻断免疫疗法的靶标。以巨噬细胞为中心的治疗方法包括：阻断肿瘤募集和存活的策略;抗肿瘤、M1样模式的功能再教育;引发细胞外杀伤或吞噬癌细胞的肿瘤定向单克隆抗体。我们推测TAM可以提供定制细胞减灭疗法和免疫疗法的工具，并且以TAM为中心的治疗策略具有与化疗和免疫疗法互补和协同的潜力。
Macrophages are crucial drivers of tumor-promoting inflammation. Tumor-associated macrophages (TAM) contribute to tumor progression at different levels, including promoting genetic instability, nurturing cancer stem cells, paving the way to metastasis, taming protective adaptive immunity. TAM can exert a dual, yin yang influence on the effectiveness of cytoreductive therapies (chemotherapy and radiotherapy), antagonizing antitumor activity by orchestrating a tumor-promoting, tissue repair response or, instead, contributing to their ultimate antineoplastic efficacy. TAM express triggers of checkpoints of T cell activation and are targets of checkpoint blockade immunotherapy. Macrophage-centered therapeutic approaches include: strategies to block recruitment and survival in tumors; functional reeducation to an antitumor, M1-like mode; tumor-directed monoclonal antibodies which elicit extracellular killing or phagocytosis of cancer cells. We surmise that TAM can provide tools to tailor cytoreductive therapies and immunotherapy and that TAM-centered therapeutic strategies have the potential to complement and synergize with chemotherapy and immunotherapy.